Selenium Influences Trace Elements Homeostasis, Cancer Biomarkers in Squamous Cell Carcinoma Patients Administered with Cancerocidal Radiotherapy

Document Type : Research Articles


1 Department of Life Science,School of Natural Sciences,Suwon University,312, Wau-ri, Bongdam -eup,Hwaseong-si,Gyeonggi - do, 445- 743., Republic of Korea.

2 Department of Biochemistry, VRR Institute of BioMedical Sciences, University of Madras, Kattupakkam, Chennai, India.

3 Department of Biotechnology, University of Madras,Chennai, India.

4 Human Genetics Laboratory, Sree Balaji Dental College and Hospital and Sree Balaji Medical College and Hospital, Bharath Institute of Higher Education and Research, Pallikaranai, Chennai, India.


In the perspective of selenium as an antioxidant and anti-carcinogen, so far no strong intervention trials with
selenium over radiation-treated oral squamous cell carcinoma cases have been conducted, to examine the response of
the disease and the subsequent biochemical alterations. In the present study, untreated oral cancer cases (Gp II) were
compared with radiation-treated groups with and without selenium (Gp IIa, IIb), forward to find the trace elements
and cancer biomarkers status, at a follow-up of 6 months. Severe alteration in the trace elements levels of Se, Cu,
Fe, Zn, Na, K, Ca, Cl, were noticed in Gp II. Though Gp IIa showed slight improvement, administration of selenium
(Gp IIb) improved the level of all these elements to a greater extent (p<0.001). GpII and IIa showed increased level of
bio markers 5’-nucleotidase, PschE, LAP, γ-GTP, LDH, SGOT, SGPT, ACP, ALP, CPK, TNF, CEA, AFP, Scc-Ag.
The greater extent of restitution to near normalcy was observed in patients given selenium (Gp IIb) (p<0.001). Owing to
the fact that selenium scavengers oxidants and hence decelerate carcinogenesis by eliminating tumors, so the tumor
released constituents into the systemic circulation declined significantly. Therefore, the outcome of the study suggests
selenium as a valuable therapeutic measure as adjuvant for oral cancer patients undergoing cancerocidal radiotherapy.


Main Subjects